Peroxisome proliferator-activated receptor γ C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy

Clinical Genetics

Volumn 64, Issue 5, 2003, Pages 398-403

  Song, J ^a   Sakatsume, Minoru ^a   Narita, I ^a   Goto, S ^a   Omori, K ^a   Takada, T ^a   Saito, N ^a   Ueno, M ^a   Gejyo, F ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

IgA nephropathy; Polymorphism; PPAR ; Renal survival

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENOMIC DNA; GLUCOCORTICOID; IMMUNOGLOBULIN A; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TYROSINE;

ADULT; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DISEASE COURSE; DNA ISOLATION; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOREGULATION; INSULIN SENSITIVITY; JAPAN; KAPLAN MEIER METHOD; KIDNEY BIOPSY; KIDNEY FAILURE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL;

ADULT; ALLELES; FEMALE; GENOTYPE; GLOMERULONEPHRITIS, IGA; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 0242441640     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2003.00154.x     Document Type: Article

References (26)

1. Galla JH. IgA nephropathy. Kidney Int 1995: 47 (2): 377-387.
2. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 1997: 29 (4): 526-532.
3. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988: 12 (5): 340-347.
4. Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001: 110 (6): 434-437.
5. Hsu S, Ramirez S, Winn M et al. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 2000: 57 (5): 1818-1835.
6. Rantala I, Mustonen J, Hurme M et al. Pathogenetic aspects of IgA nephropathy. Nephron 2001: 88 (3): 193-198.
7. Scolari F, Amoroso A, Savoldi S et al. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis 1999: 33 (5): 857-865.
8. Alamartine E, Sabatier JC, Guerin C et al. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991: 18 (1): 12-19.
9. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990: 347 (6294): 645-650.
10. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001: 60 (1): 14-30.
11. Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biol 2002: 71 (3): 388-400.
12. Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - an update. Toxicol Pathol 2001: 29 (2): 224-231.
13. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000: 49 (10): 497-505.
14. Ma LJ, Marcantom C, Linton MF et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001: 59 (5): 1899-1910.
15. Buckingham RE, Al-Barazanji KA, Toseland CD et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998: 47 (8): 1326-1334.
16. Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002: 3 (2): 59-70.
17. Oates JC, Reilly CM, Crosby MB et al. Peroxisome proliferator-activated receptor agonists: Potential use for treating chronic inflammatory diseases. Arthritis Rheum 2002: 46 (3): 598-605.
18. Yang XY, Wang LH, Chen T et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPAR-gamma co association with transcription factor NFAT. J Biol Chem 2000: 275 (7): 4541-4544.
19. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001: 169 (3): 453-459.
20. Shiomi T, Tsutsui H, Hayashidani S et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002: 106 (24): 3126-3132.
21. Fajas L, Fruchart JC, Auwerx J. PPARg3 mRNA: A distinct PPARg mRNA subtype transcribed from an independent promoter. FEBS Lett 1998: 438: 55-60.
22. Zhu Y, Qi C, Korenberg JR et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 1995: 92 (17): 7921-7925.
23. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161 ->T polymorphism and coronary artery disease. Cardiovasc Res 1999: 44 (3): 588-594.
24. Suzuki S, Sato H, Kobayashi H et al. Comparative study of IgA nephropathy with acute and insidious onset. Clinical, laboratory and pathological findings. Am J Nephrol 1992: 12 (12): 2228.
25. Takano H, Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J Diabetes Complications 2002: 16 (1): 108-114.
26. Imazu M. Hypertension and insulin disorders. Curr Hypertens Rep 2002: 4 (6): 477-482.